These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 12684587)

  • 1. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
    Seidman EG
    Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].
    Corominas H; Díaz C; Vázquez G; Baiget M
    Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
    Sanderson J; Ansari A; Marinaki T; Duley J
    Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
    Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
    J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Cao Q; Zhu Q; Shang Y; Gao M; Si J
    Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.
    Clunie GP; Lennard L
    Rheumatology (Oxford); 2004 Jan; 43(1):13-8. PubMed ID: 14566029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.
    Fargher EA; Tricker K; Newman W; Elliott R; Roberts SA; Shaffer JL; Bruce I; Payne K
    J Clin Pharm Ther; 2007 Apr; 32(2):187-95. PubMed ID: 17381669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
    Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurines in Crohn's disease, is there something new?
    Miheller P; Lakatos PL
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1505-14. PubMed ID: 20919963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine therapy in inflammatory bowel disease.
    Ha C; Dassopoulos T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.
    Zhu Q; Cao Q
    Chin Med J (Engl); 2012 Oct; 125(20):3665-70. PubMed ID: 23075721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.